Phase II Study of the A-ICOX Regimen Consisting of Bevacizumab (Avastin), Intermittent Dose Capecitabine (Xeloda) and Oxaliplatin (Eloxatin) in Patients With Untreated Advanced Colorectal Cancer.

Trial Profile

Phase II Study of the A-ICOX Regimen Consisting of Bevacizumab (Avastin), Intermittent Dose Capecitabine (Xeloda) and Oxaliplatin (Eloxatin) in Patients With Untreated Advanced Colorectal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2011 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 05 May 2009 Planned end date changed from Dec 2008 to Dec 2009 as reported by ClinicalTrials.gov.
    • 16 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top